OMass Announces Publication in Nature Methods
OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, announces the publication of a novel, highly enabling native mass spectrometry approach that marks a significant technical advance in the field. In this study OMass scientists, in collaboration with researchers from Oxford University, the Karolinska Institute and Thermo Fisher Scientific, describe the development of a top-down mass spec methodology. The development allows definition of the lipidome/metabolome in contact with the protein complex of interest and was supported by MD simulations carried out at the University of Southampton. The development of the new tribrid Orbitrap MS instrument was the result of OMass and Oxford university scientists working closely with a team at Thermo Fisher Scientific. The article was published in the 5th May 2020 print issue of Nature Methods